Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough arthritis cases?

NCT ID NCT07412704

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 3 times

Summary

This early-stage study tests a new drug, BMS-986528, in 84 adults with rheumatoid arthritis that hasn't responded well to other treatments. The main goal is to check safety and how the body processes the drug. Researchers will also look for signs that it might help control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria \- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat. Exclusion Criteria * Juvenile arthritis or onset of inflammatory arthritis before age 18. * Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out. * Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis rheumatoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis rheumatoid

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    38 sites in 11 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charité Research Organisation

    RECRUITING

    Berlin, 10117, Germany

  • Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

  • Local Institution - 0001

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200127, China

  • Local Institution - 0006

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100091, China

  • Local Institution - 0007

    NOT_YET_RECRUITING

    Nanchang, Jiangxi, 330006, China

  • Local Institution - 0010

    NOT_YET_RECRUITING

    Zhengzhou, Henan, 450000, China

  • Local Institution - 0017

    NOT_YET_RECRUITING

    Roma, 00168, Italy

  • Local Institution - 0019

    NOT_YET_RECRUITING

    Rozzano, Milano, 20089, Italy

  • Local Institution - 0020

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

  • Local Institution - 0021

    NOT_YET_RECRUITING

    Cologne, 50937, Germany

  • Local Institution - 0023

    NOT_YET_RECRUITING

    Józefów, Masovian Voivodeship, 05-410, Poland

  • Local Institution - 0027

    NOT_YET_RECRUITING

    Geneva, 1211, Switzerland

  • Local Institution - 0028

    NOT_YET_RECRUITING

    Herne, 44652, Germany

  • Local Institution - 0033

    NOT_YET_RECRUITING

    Porto Alegre, Rio Grande do Sul, 90050-010, Brazil

  • Local Institution - 0037

    NOT_YET_RECRUITING

    Bern, 3010, Switzerland

  • Local Institution - 0039

    NOT_YET_RECRUITING

    A Coruña, A Coruña [La Coruña], 15006, Spain

  • Local Institution - 0040

    NOT_YET_RECRUITING

    München, Bavaria, 81377, Germany

  • Local Institution - 0048

    NOT_YET_RECRUITING

    Merksem, Flanders, 2170, Belgium

  • Local Institution - 0049

    NOT_YET_RECRUITING

    Leuven, 3000, Belgium

  • Local Institution - 0050

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

  • Local Institution - 0051

    WITHDRAWN

    DeSoto, Texas, 75115, United States

  • Local Institution - 0053

    NOT_YET_RECRUITING

    México, 14080, Mexico

  • Local Institution - 0055

    NOT_YET_RECRUITING

    South Miami, Florida, 33143, United States

  • Local Institution - 0058

    NOT_YET_RECRUITING

    Córdoba, Córdoba, 14004, Spain

  • Local Institution - 0060

    NOT_YET_RECRUITING

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76008, Ukraine

  • Local Institution - 0061

    NOT_YET_RECRUITING

    Ternopil, 46002, Ukraine

  • Local Institution - 0063

    NOT_YET_RECRUITING

    Poltava, Poltava Oblast, 36011, Ukraine

  • Local Institution - 0064

    NOT_YET_RECRUITING

    Kyiv, Kyiv Oblast, 01135, Ukraine

  • Local Institution - 0066

    NOT_YET_RECRUITING

    Portland, Oregon, 97239, United States

  • Local Institution - 0068

    NOT_YET_RECRUITING

    La Jolla, California, 92037, United States

  • Local Institution - 0069

    NOT_YET_RECRUITING

    Palo Alto, California, 94304-2210, United States

  • Local Institution - 0070

    NOT_YET_RECRUITING

    Loma Linda, California, 92354, United States

  • Local Institution - 0071

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Local Institution - 0079

    NOT_YET_RECRUITING

    New York, New York, 10029, United States

  • Local Institution - 0080

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, 510260, China

  • Local Institution - 0081

    NOT_YET_RECRUITING

    New York, New York, 10016, United States

  • Local Institution - 0082

    NOT_YET_RECRUITING

    Valinhos, São Paulo, 13271-130, Brazil

  • Local Institution - 0083

    NOT_YET_RECRUITING

    Aparecida de Goiânia, Goiás, 74935-530, Brazil

  • St. Josef-Stift Sendenhorst

    RECRUITING

    Sendenhorst, 48324, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.